Drug Policy and Evaluation

The ODPRN has conducted multiple studies that have both informed and evaluated the impact of drug policies in Ontario, and more broadly across Canada.  This research includes a wide breadth of work ranging from large drug class reviews to specific rapid response projects resulting from decision makers’ pressing initiatives.

New Research

Current and Prospective Utilization of Innovator Biologics and Biosimilars in Ontario

Biologic drugs are important treatment options across a wide number of medical conditions, including rheumatic conditions, gastrointestinal disease, and diabetes. Although these drugs have had a measurable impact on patient outcomes, their substantial cost and growth in use threatens the sustainability of public drug programs. A biosimilar biologic drug, or biosimilar, is a drug that is highly similar and has no clinically meaningful differences to an innovator biologic. Biosimilars can also be developed at a lower cost and therefore offer an opportunity to reduce public drug spending.

Unfortunately, biosimilars are underutilized and as a result, public payers in Canada have begun developing policies designed to increase the use of biosimilar drugs. Essential to this work is a better understanding of biologics and biosimilars use across various clinical conditions.

This report describes the current and prospective utilization patterns and expenditures of innovator biologics and biosimilars through the public drug program in Ontario, Canada.

CADTH summarizes this report in “Utilization of Innovator Biologics and Biosimilars for Chronic Inflammatory Diseases in Canada: A Provincial Perspective” and discusses potential implications for decision-makers.

All Research on Drug Policy and Evaluation

wdt_ID Title Publication Type Date Released Clinical Topic Additional Resources
wdt_ID Title Publication Type Date Released Clinical Topic Additional Resources
1 Low molecular weight heparin Drug Class Review 01 May 2016 Cardiovascular Health Research Summary
2 The influence of socioeconomic status on selection of anticoagulation for atrial fibrillation Journal Article 25 Feb 2016 Cardiovascular Health
3 Impact of the JUPITER trial on statin prescribing for primary prevention Journal Article 12 Aug 2013 Cardiovascular Health
4 Trends in the coprescription of proton pump inhibitors with clopidogrel: An ecological analysis Journal Article 26 Nov 2015 Cardiovascular Health
5 Antipsychotics in the elderly Drug Class Review 01 May 2015 Dementia and Antipsychotics Research Summary
6 Cognitive enhancers for Alzheimer's Disease Drug Class Review 01 Aug 2015 Dementia and Antipsychotics Research Summary
7 Association of a blood glucose test strip quantity-limit policy with patient outcomes: A population-based study Journal Article 07 Nov 2016 Diabetes Research Minute
8 Adherence to prescribing recommendations made on a provincial formulary Journal Article 01 May 2014 Diabetes Research Minute
9 Blood glucose test strips: Options to reduce usage Journal Article 12 Jan 2010 Diabetes Letter to Editor
10 The impact of policies to reduce blood glucose test strip utilization and costs in Canada Journal Article 01 Jun 2015 Diabetes Research Minute
Please note that this report is NOT COMPLETE and is still in progress. Click below if you would like to continue.